Albireo Pharma Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Albireo Pharma Inc.
Business Development Remains Top Priority For Ipsen
CEO David Loew tells Scrip that Ipsen’s prodigious dealmaking over the past couple of years is set to continue, on top of the acquisition of Albireo announced last month.
Deals In 2023: Partnerships And Modest M&A
Mid-sized M&A, collaborations, creative financing, and biotech consolidation will feature in 2023. IPOs and follow-ons play bit-parts.
Stock Watch: J.P. Morgan Conference, Big Splash News And Stock Prices
Timing big M&A transactions to coincide with the biggest investor conference of the year is difficult. But getting it right can boost stocks across the sector.
FDA’s Robyn Bent On The Evolution of Patient-Focused Drug Development
The director of the agency’s patient-focused drug development program talks about how the program has improved the development and evaluation of new drugs, initiatives underway, and plans to standardize and harmonize the process.
- Other Names / Subsidiaries
- Albireo AB
- Biodel Inc.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.